-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, Gerry Pharmaceuticals announced that its partner Sagimet Biosciences has completed the first patient administration of its non-alcoholic steatohepatitis (NASH) phase IIb clinical trial (FASCINATE-2)
Primary efficacy endpoint:
1.
2.
The US Food and Drug Administration (FDA) has approved the two primary efficacy endpoints of the NASH Phase IIb study
In March 2021, Gan Lai Pharmaceutical Co.
Gale has all indications for fatty acid synthase inhibitors (FASN) including ASC40 (TVB-2640) and all related compounds, including non-alcoholic steatohepatitis (NASH) and tumors developed, manufactured and commercialized in Greater China Exclusive rights
Note: The original text has been deleted